{"doi":"10.1093/ofid/ofae202","title":"Remdesivir is Associated with Reduced Mortality in Patients Hospitalized for COVID-19 Not Requiring Supplemental Oxygen","abstract":"Background: Remdesivir has demonstrated benefit in some hospitalized patients with coronavirus disease 2019 (COVID-19) on supplemental oxygen and in nonhospitalized patients breathing room air. The durability of this benefit across time periods with different circulating severe acute respiratory syndrome coronavirus 2 variants of concern (VOC) is unknown. This comparative effectiveness study in patients hospitalized for COVID-19 and not receiving supplemental oxygen at admission compared those starting remdesivir treatment in the first 2 days of admission with those receiving no remdesivir during their hospitalization across different VOC periods. Method: Using a large, multicenter US hospital database, in-hospital mortality rates were compared among patients hospitalized for COVID-19 but not requiring supplemental oxygen at admission between December 2020 and April 2022. Patients receiving remdesivir at hospital admission were matched 1:1 to those not receiving remdesivir during hospitalization, using propensity score matching. Cox proportional hazards models were used to assess 14- and 28-day in-hospital mortality rates or discharge to hospice. Results: Among the 121 336 eligible patients, 58 188 remdesivir-treated patients were matched to 17 574 unique patients not receiving remdesivir. Overall, 5.4% of remdesivir-treated and 7.3% in the non-remdesivir group died within 14 days, and 8.0% and 9.8%, respectively, died within 28 days. Remdesivir treatment was associated with a statistically significant reduction in the in-hospital mortality rate compared with non-remdesivir treatment (14-day and 28-day adjusted hazard ratios [95% confidence interval], 0.75 [0.68-0.83] and 0.83 [0.76-0.90], respectively). This significant mortality benefit endured across the different VOC periods. Conclusions: Remdesivir initiation in patients hospitalized for COVID-19 and not requiring supplemental oxygen at admission was associated with a significantly reduced in-hospital mortality rate. These findings highlight a potential survival benefit when clinicians initiated remdesivir on admission across the dominant variant eras of the evolving pandemic.","journal":"Open Forum Infectious Diseases","year":2024,"id":430663,"datarank":0.0,"base_score":0.0,"endowment":0.0,"self_citation_contribution":0.0,"citation_network_contribution":0.0,"self_endowment_contribution":0.0,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":18,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":0.9594,"is_data_producer":false,"deposit_databanks":null,"is_oa":true,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":"2024-01-01","fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":1233991,"name":"Aastha Chandak","orcid":"0000-0001-5653-435X","position":1,"is_corresponding":false},{"id":1189227,"name":"Chidinma Chima-Melton","orcid":"0000-0003-0730-9871","position":2,"is_corresponding":false},{"id":103430,"name":"André C. Kalil","orcid":"0000-0002-6489-6294","position":3,"is_corresponding":false},{"id":400070,"name":"Heng Jiang","orcid":"0000-0001-8394-6077","position":4,"is_corresponding":false},{"id":1233992,"name":"Eunyoung Lee","orcid":"0000-0001-8280-3605","position":5,"is_corresponding":false},{"id":1234511,"name":"Celine Der-Torossian","orcid":null,"position":6,"is_corresponding":false},{"id":606932,"name":"Mark Thrun","orcid":"0000-0001-8368-496X","position":7,"is_corresponding":false},{"id":1233993,"name":"Mark Berry","orcid":"0000-0002-8534-2012","position":8,"is_corresponding":false},{"id":525746,"name":"Richard Haubrich","orcid":"0000-0002-9435-2386","position":9,"is_corresponding":false},{"id":646873,"name":"Robert L. Gottlieb","orcid":"0000-0001-8376-8709","position":10,"is_corresponding":false},{"id":1234510,"name":"Essy Mozaffari","orcid":null,"position":0,"is_corresponding":true}],"reference_count":23,"raw_metadata":null,"created_at":"2026-07-19T01:59:20.861374Z","pmid":"38894848","pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}